TDS Pharm Co (XKRX:464280) Retained Earnings : ₩29,294 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is TDS Pharm Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. TDS Pharm Co's retained earnings for the quarter that ended in Dec. 2024 was ₩29,294 Mil.

TDS Pharm Co's quarterly retained earnings increased from Mar. 2024 (₩26,544 Mil) to Sep. 2024 (₩28,698 Mil) and increased from Sep. 2024 (₩28,698 Mil) to Dec. 2024 (₩29,294 Mil).

TDS Pharm Co's annual retained earnings increased from Dec. 2022 (₩21,260 Mil) to Dec. 2023 (₩25,736 Mil) and increased from Dec. 2023 (₩25,736 Mil) to Dec. 2024 (₩29,294 Mil).

TDS Pharm Co Retained Earnings Historical Data

The historical data trend for TDS Pharm Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TDS Pharm Co Retained Earnings Chart

TDS Pharm Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

15,741.44

17,804.29

21,259.90

25,735.53

29,293.53

TDS Pharm Co Quarterly Data
	Dec20	Dec21	Dec22	Mar23	Sep23	Dec23	Mar24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial				-	25,735.53	26,544.49	28,697.75	29,293.53

TDS Pharm Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

TDS Pharm Co (XKRX:464280) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

TDS Pharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TDS Pharm Co Ltd (XKRX:464280) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

253 Pangyo-ro, Pangyo Inno Valley, Building C, Room 403, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486

Website

https://www.tdspharm.com

TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.

TDS Pharm Co Headlines

No Headlines